# SynerGIST-1st Line (NCT07406633)

> KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07406633
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Kumquat Biosciences Inc.
- Conditions: GIST - Gastrointestinal Stromal Tumor; GIST; GIST Metastatic Cancer; Gastro Intestinal Stromal Tumour; Gastrointestinal Tumors
- Interventions: KQB198; Imatinib (Gleevec)
- Enrollment: 46
- Primary outcome: Objective response rate (ORR)

## Indexed commentary on SynerGIST-1st Line so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=synergist-1st-line-nct07406633